Drugs /

sodium selenite

Back to Drugs List

Overview

NCI Definition [1]:
An inorganic form of the trace element selenium with potential antineoplastic activity. Selenium, administered in the form of sodium selenite, is reduced to hydrogen selenide (H2Se) in the presence of glutathione (GSH) and subsequently generates superoxide radicals upon reaction with oxygen. This may inhibit the expression and activity of the transcription factor Sp1; in turn Sp1 down-regulates androgen receptor (AR) expression and blocks AR signaling. Eventually, selenium may induce apoptosis in prostate cancer cells and inhibit tumor cell proliferation.

Clinical Trials

View Clinical Trials for sodium selenite

Sodium selenite has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating sodium selenite, 1 is phase 1 (0 open).

Prostate adenocarcinoma is the most common disease being investigated in sodium selenite clinical trials [2].

Drug Details

Synonyms [2]:
sodium selenite [chemical/ingredient], sodium selenite, selenious acid, sodium salt (1:2), selenite, sodium, selenious acid, disodium salt, selenious acid disodium salt, selenite, disodium, sodium selenite (substance), sodium selenite, disodium selenium trioxide, selenous acid, disodium salt, selenous acid disodium salt, disodium selenite, sodium selenite
NCIT ID [1]:
C87346
SNOMED ID [1]:
C-71091

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.